Cargando…

LB9. The Effect of Initiating Integrase Inhibitor-based vs. Non-Nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy on Progression to Diabetes among North American Persons in HIV Care

BACKGROUND: Integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) has been implicated in greater weight gain than other regimens among people with HIV, but there is little evidence about its role in serious clinical outcomes proximal to weight gain. We therefore examined the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rebeiro, Peter F, Jenkins, Cathy, Bian, Aihua, Lake, Jordan, Bourgi, Kassem, Horberg, Michael A, Moore, Richard, Altoff, Keri, Klein, Marina, Eron, Joseph J, Gill, M John, Kitahata, Mari, Napravnik, Sonia, Silverberg, Michael, Mayor, Angel M, Willig, Amanda, Floris-Moore, Michelle, Sterling, Timothy, Koethe, John R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810257/ http://dx.doi.org/10.1093/ofid/ofz415.2492

Ejemplares similares

Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada
por: Bourgi, Kassem, et al.
Publicado: (2020)

Weight Gain After Switch from Efavirenz-Based to Integrase Inhibitor-Based Regimens
por: Norwood, Jamison, et al.
Publicado: (2017)

Integrase Inhibitor Prescribing Disparities in the DC and Johns Hopkins HIV Cohorts
por: Monroe, Anne K, et al.
Publicado: (2021)

Weight gain post-ART in HIV+ Latinos/as differs in the USA, Haiti, and Latin America
por: Coelho, Lara E., et al.
Publicado: (2022)

Health outcomes among HIV-positive Latinos initiating antiretroviral therapy in North America versus Central and South America
por: Cesar, Carina, et al.
Publicado: (2016)

2492. Differences between Individuals Currently Taking Integrase Inhibitor (INSTI)-based Therapy and Those Not Taking INSTIs in the Era of INSTIs as Recommended First-line Therapy
por: Monroe, Anne K, et al.
Publicado: (2019)

1286. Healthcare Provider Attitudes and Knowledge Around Pre-Exposure Prophylaxis (PrEP) for the Prevention of HIV-Infection in Tennessee
por: Moore, Emily, et al.
Publicado: (2019)

Geographic Variations in Retention in Care among HIV-Infected Adults in the United States
por: Rebeiro, Peter F., et al.
Publicado: (2016)

Strong Agreement of Nationally Recommended Retention Measures from the Institute of Medicine and Department of Health and Human Services
por: Rebeiro, Peter F., et al.
Publicado: (2014)

Projecting the age-distribution of men who have sex with men receiving HIV treatment in the United States
por: Kasaie, Parastu, et al.
Publicado: (2022)

Tennessee Healthcare Provider Practices, Attitudes, and Knowledge Around HIV Pre-Exposure Prophylaxis
por: Moore, Emily, et al.
Publicado: (2020)

538. Integrase Inhibitor-Based HAART Is Associated with Greater BMI Gains in Blacks, Hispanics, and Women
por: Bedimo, Roger, et al.
Publicado: (2018)

Incidence of cardiometabolic outcomes among people living with HIV‐1 initiated on integrase strand transfer inhibitor versus non‐integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States
por: Rebeiro, Peter F., et al.
Publicado: (2023)

HIV-1 Protease, Reverse Transcriptase, and Integrase Variation
por: Rhee, Soo-Yon, et al.
Publicado: (2016)

Health Disparities in Hepatitis C Screening and Linkage to Care at an Integrated Health System in Southeast Michigan
por: Bourgi, Kassem, et al.
Publicado: (2016)

1528 Ralteragir Containing regimen, for Post Exposure Prophylaxis (PEP), well tolerated in Health Care Workers (HCW)
por: Bourgi, Kassem, et al.
Publicado: (2014)

Association between U.S. State AIDS Drug Assistance Program (ADAP) Features and HIV Antiretroviral Therapy Initiation, 2001–2009
por: Hanna, David B., et al.
Publicado: (2013)

Cervical cancer epidemiology among HIV-infected women in North America
por: D’Souza, Gypsyamber, et al.
Publicado: (2010)

Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model
por: Althoff, Keri N, et al.
Publicado: (2019)

CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?
por: Althoff, Keri N, et al.
Publicado: (2010)

Genetic architecture of cardiometabolic risks in people living with HIV
por: Chang, Haoxiang, et al.
Publicado: (2020)

Correction to: Genetic architecture of cardiometabolic risks in people living with HIV
por: Cheng, Haoxiang, et al.
Publicado: (2021)

Clinical Impact of Nucleic Acid Amplification Testing in the Diagnosis of Mycobacterium Tuberculosis: A 10-Year Longitudinal Study
por: Bourgi, Kassem, et al.
Publicado: (2017)

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
por: Smith, Steven J., et al.
Publicado: (2014)

Smoking and Predictors of Pneumonia Among HIV-Infected Patients Receiving Care in the HAART Era
por: Murdoch, David M, et al.
Publicado: (2008)

Mortality following myocardial infarction among HIV-infected persons: the Center for AIDS Research Network Of Integrated Clinical Systems (CNICS)
por: Feinstein, Matthew J., et al.
Publicado: (2019)

Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)
por: Eron, J, et al.
Publicado: (2010)

Factors associated with severity of COVID-19 disease in a multicenter cohort of people with HIV in the United States, March-December 2020
por: Shapiro, Adrienne E., et al.
Publicado: (2021)

Resistance to Integrase Inhibitors
por: Métifiot, Mathieu, et al.
Publicado: (2010)

Racial and ethnic disparities in COVID-19 disease incidence independent of comorbidities, among people with HIV in the US
por: Bender Ignacio, RA, et al.
Publicado: (2021)

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
por: Himmel, Daniel M., et al.
Publicado: (2020)

1987. "Association Between Integrase Inhibitor Plasma Concentrations and Body Weight Gain in Women Living with HIV"
por: Lahiri, Cecile D, et al.
Publicado: (2023)

Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations
por: Winters, Mark A., et al.
Publicado: (2012)

Loss to Clinic and Five-Year Mortality among HIV-Infected Antiretroviral Therapy Initiators
por: Edwards, Jessie K., et al.
Publicado: (2014)

Mortality after cancer diagnosis among HIV-infected individuals in the CFAR Network of Integrated Clinical Systems (CNICS)
por: Achenbach, Chad, et al.
Publicado: (2010)

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study
por: Underwood, Mark, et al.
Publicado: (2022)

Failure to decrease HbA1c levels following TB treatment is associated with elevated Th1/Th17 CD4+ responses
por: Krause, Robert, et al.
Publicado: (2023)

32. Influenza Vaccination Prevalence Among Adults with and without HIV by Race, Age, and Sex
por: Levine-Hall, Tory, et al.
Publicado: (2020)

Recent cancer incidence trends in an observational clinical cohort of HIV-infected patients in the US, 2000 to 2011
por: Yanik, Elizabeth L, et al.
Publicado: (2013)

HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors
por: Koneru, Pratibha C, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_g9rpsi0bak77p2n8p0hspgjqg4